Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis
| Autor: | Ru‐Lin Zhao, Li‐ya Zhu‐ge, Shuang Wu, Youhua Wang, Zhen Li, Yong Xie |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Furazolidone medicine.drug_class Antibiotics Cochrane Library law.invention Helicobacter Infections 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans Adverse effect biology Helicobacter pylori business.industry Incidence (epidemiology) Gastroenterology General Medicine biology.organism_classification Anti-Bacterial Agents Infectious Diseases Treatment Outcome 030220 oncology & carcinogenesis Relative risk 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Helicobacter. 23(2) |
| ISSN: | 1523-5378 |
| Popis: | Antibiotic resistance is a major cause of Helicobacter pylori (H. pylori) treatment failures. Because the resistance rate of H. pylori to furazolidone is low, we aimed to assess the efficacy and safety of furazolidone. We searched the PubMed, Web of Science, Cochrane Library, and Embase databases and included randomized controlled trials (RCT) that either compared furazolidone to other antibiotics or changed the administered dose of furazolidone. A total of 18 articles were included in the meta-analysis. According to the intention-to-treat (ITT) analysis, the total eradication rates of furazolidone-containing therapy were superior to those of other antibiotic-containing therapies (relative risk [RR] 1.07, 95% confidence interval [CI] 1.01-1.14) (13 RCTs). Specifically, the eradication rates of furazolidone-containing therapy were better than those for metronidazole-containing therapy (RR 1.10, 95% CI: 1.01-1.21 for ITT). The eradication rate of furazolidone-containing bismuth-containing quadruple therapy was 92.9% (95% CI: 90.7%-95.1%) (PP). In addition, a higher daily dose of furazolidone increased the eradication rate (RR 1.17, 95% CI: 1.05-1.31). And the incidence of some adverse effects, such as fever and anorexia, was higher in the furazolidone group than in the control group, the overall incidences of total side effects and severe side effects showed no significant differences between the groups. Furazolidone-containing treatments could achieve satisfactory eradication rates and did not increase the incidence of total or severe adverse effects, but the incidence of milder side effects, such as fever and anorexia, should be considered when prescribing furazolidone-containing treatments to patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text